Profile of primary resistance in HIV-1-infected treatment-naive individuals from Western India.
The majority of the HIV drug resistance (HIVDR) testing studies have focused on subtype B virus. The predominance of subtype C in the Indian subcontinent along with greater access to antiretroviral therapy (ART) necessitates studies on HIVDR genotyping. We determined the prevalence of mutations associated with protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI), and nonnucleoside reverse transcriptase inhibitors (NNRTI) from plasma of 40 antiretroviral drug-naive study participants in Indian HIV-1 pol gene sequences. Of these, 36 sequences belonged to subtype C, two to subtype A1, and two were subtype A1C recombinants. The heterosexual route was the most common route of transmission. Drug resistance-associated mutations were observed in 10% (4/40) of the study participants. The resistance mutation observed in the protease gene was V82A, whereas in the RT gene, M41L, D67N, M184V, and A98G were documented. This is the first study reporting major protease mutations by genotyping in ART-naive individuals from western India.
Lall
Mahima
M
Department of Microbiology, Armed Forces Medical College, Pune, India.
Gupta
R M
RM
Sen
Sourav
S
Kapila
Ketoki
K
Tripathy
S P
SP
Paranjape
R S
RS
D024882:Drug Resistance, Viral / Q000187:drug effects / Q000235:genetics*; D015751:Genes, pol / Q000235:genetics*; D015658:HIV Infections / Q000821:virology*; D017320:HIV Protease Inhibitors / Q000494:pharmacology; D015497:HIV-1 / Q000145:classification / Q000235:genetics*; D006801:Humans; D007194:India; D009154:Mutation; D011480:Protease Inhibitors / Q000494:pharmacology; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology
D017320:HIV Protease Inhibitors; D011480:Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors